Lonza jumps 3.8% after Sfr2.25bn rights issue wins approval from shareholders

By Aidan Gregory
26 Apr 2017

Shares in Lonza, the Swiss pharmaceutical company, closed 3.8% higher on Wednesday after it launched its Sfr2.25bn rights issue to partly finance its acquisition of Capsugel from KKR, having secured approval from its shareholders at its annual general meeting on Tuesday.

The deal, underwritten by UBS and Bank of America Merrill Lynch, will consist of 22m new shares at Sfr136 a share. That is a 33% discount to Lonza's closing price on Tuesday.

Lonza announced the $5.5bn acquisition of Capusugel, a specialist maker of capsule shells for pharmaceutical companies, ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.